The challenge of selecting tumor antigens for chimeric antigen receptor T-cell therapy in ovarian cancer-Reference-Cited by-同舟云学术

The challenge of selecting tumor antigens for chimeric antigen receptor T-cell therapy in ovarian cancer

Published:2022-09-29 Issue:12 Volume:39 Page:
ISSN:1559-131X
Container-title:Medical Oncology
language:en
Short-container-title:Med Oncol

Author:

Ding Haigang,Zhang Juan,Zhang Feng,Xu Yan,Yu Yijun,Liang Wenqing^ORCID,Li Qingping

Funder

Public Technology Applied Research Projects of Zhejiang Province

Medical and Health Research Project of Zhejiang Province

Traditional Chinese Medicine Science and Technology Projects of Zhejiang Province

Research Fund Projects of The Affiliated Hospital of Zhejiang Chinese Medicine University

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology,Hematology,General Medicine

Link

https://link.springer.com/content/pdf/10.1007/s12032-022-01824-7.pdf

Reference86 articles.

1. Ovarian cancer statistics. [cited 2021 7.1.2021]; Available from: https://www.wcrf.org/dietandcancer/ovarian-cancer-statistics/.

2. Yan W, Hu H, Tang B. Advances of chimeric antigen receptor T cell therapy in ovarian cancer. Onco Targets Ther. 2019;12:8015.

3. Webb PM, Jordan SJ. Epidemiology of epithelial ovarian cancer. Best Pract Res Clin Obstet Gynaecol. 2017;41:3–14.

4. Ovarian Cancer Stages. [cited 2021 1.7.2021]; Available from: https://www.cancer.org/cancer/ovarian-cancer/detection-diagnosis-staging/staging.html.

5. Bookman M. Standard treatment in advanced ovarian cancer in 2005: the state of the art. Int J Gynecol Cancer. 2005;15:Suppl 3.

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. CAR-NK cell therapy in AML: Current treatment, challenges, and advantage;Biomedicine & Pharmacotherapy;2024-08

2. CAR-T Cell Therapy in Ovarian Cancer: Where Are We Now?;Diagnostics;2024-04-16

3. CRISPR, CAR-T, and NK: Current applications and future perspectives;Genes & Diseases;2023-09